Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Ustekinumab shows potential therapeutic benefit in perianal Crohn's Disease

22 Nov 2020

Use of ustekinumab appears effective in the treatment of perianal refractory Crohn’s disease (pCD), suggests a recent study.

A national multicentre retrospective cohort study was carried out involving patients with either active or inactive pCD who received ustekinumab. In patients with active pCD at treatment initiation, the success of ustekinumab was defined by clinical success at 6 months assessed by the physician’s judgment without additional medical or surgical treatment for pCD.

The authors performed univariate and multivariate logistic regression analyses to identify predictors of success. They also calculated the pCD recurrence-free survival in patients with inactive pCD at ustekinumab initiation using the Kaplan-Meier method.

In total, 207 patients (mean age, 37.7 years) were analysed. Participants had a mean CD duration of 14.3 years and mean number of prior perianal surgeries of 2.8. Of the patients, 205 (99 percent) had been previously exposed to at least one antitumour necrosis factor (anti-TNF) and 58 (28 percent) to vedolizumab. Median follow-up time was 48 weeks.

Fifty-six (27 percent) patients discontinued therapy after a median time of 43 weeks. Fifty-seven of 148 (38.5 percent) patients with active pCD achieved success. Among those with setons at initiation, 29 of 88 (33 percent) had a successful removal. Treatment success correlated with the absence of optimization (odds ratio [OR], 2.74, 95 percent confidence interval [CI], 0.96–7.82; p=0.044).

Multivariable analysis revealed that the number of prior anti-TNF (3) was borderline significant (OR, 0.4, 95 percent CI, 0.15–1.08; p=0.056).

Additionally, the odds of recurrence-free survival in patients with inactive pCD at initiation was 86.2 percent at week 26 and 75.1 percent at week 52.

“Further prospective studies are warranted,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.